Post by Terumo Aortic

🚀Milestone Achieved! Today we are delighted to announce that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Fenestrated TREO® Abdominal Stent-Graft system. This designation supports the potential for US physicians to treat patients whose complex anatomy or clinical conditions makes traditional endovascular devices or open surgery unsuitable – addressing a significant unmet need. Fenestrated TREO® offers a tailored, minimally invasive solution designed for challenging anatomies, including the ability to incorporate multiple fenestrations precisely aligned to a patient’s unique arterial branching pattern. This level of customization helps address the needs of patients with complex vessel configurations that off-the shelf devices can’t accommodate. #Milestone #CommitttedtoAorticCare #FenestratedTREO® 👉Read the full press release here: https://loom.ly/3uZOgKQ